Evolus EOLS Stock
$6.74
2.276170%
Add to favorites
SECTOR
COUNTRY
Exchange
Market Cap
$443.86M
LOW - HIGH [24H]
$6.53
-
$6.90
VOLUME [24H]
$547.59K
P/E Ratio
0
Earnings per share
-$0.66
ISIN
US30052C1071
Evolus Price Chart
Evolus EOLS Financial and Trading Overview
| Evolus stock price | 6.74 USD |
| Previous Close | 6.63 USD |
| Open | 6.56 USD |
| Bid | 4.8 USD x 200 |
| Ask | 8.29 USD x 200 |
| Day's Range | 6.43 - 6.68 USD |
| 52 Week Range | 3.86 - 10.2 USD |
| Volume | 362.77K USD |
| Avg. Volume | 836.72K USD |
| Market Cap | 433.98M USD |
| Beta (5Y Monthly) | 1.334 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.67 USD |
EOLS Valuation Measures
| Enterprise Value | 549.09M USD |
| Trailing P/E | N/A |
| Forward P/E | 27.458334 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.4380244 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 1.819 |
| Enterprise Value/EBITDA | -23.717 |
Trading Information
Evolus Stock Price History
| Beta (5Y Monthly) | 1.334 |
| 52-Week Change | -31.49% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 10.2 USD |
| 52 Week Low | 3.86 USD |
| 50-Day Moving Average | 5.98 USD |
| 200-Day Moving Average | 5.9 USD |
EOLS Share Statistics
| Avg. Volume (3 month) | 836.72K USD |
| Avg. Daily Volume (10-Days) | 769.01K USD |
| Shares Outstanding | 65.85M |
| Float | 50.04M |
| Short Ratio | 6.37 |
| % Held by Insiders | 14.68% |
| % Held by Institutions | 70.05% |
| Shares Short | 6.06M |
| Short % of Float | 9.32% |
| Short % of Shares Outstanding | 9.19% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -14.38% |
| Operating Margin (ttm) | -9.38% |
| Gross Margin | 66.05% |
| EBITDA Margin | -7.67% |
Management Effectiveness
| Return on Assets (ttm) | -9.055% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 301.79M USD |
| Revenue Per Share (ttm) | 4.65 USD |
| Quarterly Revenue Growth (yoy) | 6.70% |
| Gross Profit (ttm) | 199.35M USD |
| EBITDA | -23152000 USD |
| Net Income Avi to Common (ttm) | -43423000 USD |
| Diluted EPS (ttm) | -0.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 49.79M USD |
| Total Cash Per Share (mrq) | 0.76 USD |
| Total Debt (mrq) | 164.9M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.042 |
| Book Value Per Share (mrq) | -0.437 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -36585000 USD |
| Levered Free Cash Flow (ttm) | -23226376 USD |
Profile of Evolus
| Country | United States |
| State | CA |
| City | Newport Beach |
| Address | 520 Newport Center Drive |
| ZIP | 92660 |
| Phone | 949 284 4555 |
| Website | https://www.evolus.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 350 |
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Q&A For Evolus Stock
What is a current EOLS stock price?
Evolus EOLS stock price today per share is 6.74 USD.
How to purchase Evolus stock?
You can buy EOLS shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Evolus?
The stock symbol or ticker of Evolus is EOLS.
Which industry does the Evolus company belong to?
The Evolus industry is Drug Manufacturers - Specialty & Generic.
How many shares does Evolus have in circulation?
The max supply of Evolus shares is 65.85M.
What is Evolus Price to Earnings Ratio (PE Ratio)?
Evolus PE Ratio is now.
What was Evolus earnings per share over the trailing 12 months (TTM)?
Evolus EPS is -0.66 USD over the trailing 12 months.
Which sector does the Evolus company belong to?
The Evolus sector is Healthcare.
Evolus EOLS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}